Last edition
News about "ImmunityBio "
ImmunityBio Advances FDA Talks on ANKTIVA Resubmission
ImmunityBio said the FDA has requested additional information to potentially support a resubmission of the sBLA for ANKTIVA in BCG-unresponsive papillary bladder cancer, without requiring new clinical trials, with the company planning to submit the data within 30 days.
ImmunityBio | 21/01/2026 | By News Bureau | 208
USFDA Approves ImmunityBio Bladder Cancer Therapy
The United States Food and Drug Administration (USFDA) has approved ImmunityBio’s combination therapy to treat a type of bladder cancer.
ImmunityBio | 24/04/2024 | By Aishwarya | 595
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy